Christian Callebaut
机构：Gilead Sciences (Spain), Gilead Sciences (United States) · ORCID：0000-0003-4721-2572
发表论文 135 篇 · 总被引 5288 次 · h-index 34
代表论文
- Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years (2025 · The Journal of Infectious Diseases · 被引 33)
- Lenacapavir treatment–emergent HIV-1 capsid resistance mutations are frequently associated with replication defects (2026 · Science Translational Medicine · 被引 12)
- High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence (2024 · Journal of Medical Virology · 被引 12)
- Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy (2024 · Journal of Antimicrobial Chemotherapy · 被引 10)
- Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy (2024 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 9)
- Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical Isolates (2025 · Journal of Medical Virology · 被引 5)